Adrian Rawcliffe, CEO: Adaptimmune Therapeutics ADAPY Sell · Filed 23/01/17

Trade details

Type: Insider sale
Amount: $18,706.02
Shares · price: 10,057 sh · $1.86 a share
Held after: 13,351 sh
Stock: Adaptimmune Therapeutics ADAPY
Person: Adrian RawcliffeCEO
Trade date: 23/01/17
Filed: 23/01/17
Days to filing: 0 days

Sold 43.0% of holdings

Share of holding sold: 43.0%

Adaptimmune Therapeutics trades, last 26 weeks

What else happened in Adaptimmune Therapeutics around then

Filed or reported within 30 days of the trade day · 22/12/18~23/02/16

Adrian Rawcliffe's recent trades

Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$64.1K
12,700 sh
$64.1K
Filed 08/12
Traded 08/12
Adrian RawcliffeDirector
Sell10b5-1 planWave Life Sciences
Sell10b5-1 plan
Wave Life Sciences
WVE
$630K
42,000 sh
$630K
Filed 25/12/10
Traded 25/12/08
Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$314.6K
42,000 sh
$314.6K
Filed 25/12/08
Traded 25/12/08
Adrian RawcliffeDirector
Sell10b5-1 planWave Life Sciences
Sell10b5-1 plan
Wave Life Sciences
WVE
$109.4K
16,115 sh
$109.4K
Filed 25/11/14
Traded 25/11/13
Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$112.1K
16,115 sh
$112.1K
Filed 25/11/13
Traded 25/11/13